Tango Therapeutics: PRMT5 Inhibitor Vopimetostat Approaches Pivotal Testing - Buy [Seeking Alpha]
Tango Therapeutics, Inc. (TNGX)
Company Research
Source: Seeking Alpha
TNGX reported positive phase 1/2 results in 2nd-line MTAP-deleted pancreatic cancer, doubling median progression-free survival and objective response rate versus historical controls. A pivotal trial for vopimetostat in 2nd-line MTAP-deleted pancreatic cancer patients is set for 2026, with additional combination and expansion studies planned for broader indications. There is an expansion opportunity as vopimetostat is also being explored in a study targeting MTAP-deleted lung cancer patients, with data expected to be released in 2026. jittawit.21/iStock via Getty Images I'm initiating coverage of Tango Therapeutics, Inc. TNGX ) with a Buy rating because it has been able to do well in terms of developing its lead candidate from its pipeline, which is a PRMT5 More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe
Show less
Read more
Impact Snapshot
Event Time:
TNGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TNGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TNGX alerts
High impacting Tango Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TNGX
News
- Tango Therapeutics (NASDAQ:TNGX) was given a new $15.00 price target on by analysts at Stifel Nicolaus.MarketBeat
- Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Tango Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Tango Therapeutics (NASDAQ:TNGX) had its price target raised by analysts at B. Riley from $8.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Tango Therapeutics (NASDAQ:TNGX) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.MarketBeat
TNGX
Earnings
- 11/4/25 - Beat
TNGX
Sec Filings
- 11/21/25 - Form SCHEDULE
- 11/21/25 - Form 8-K
- 11/21/25 - Form S-3ASR
- TNGX's page on the SEC website